Molecular patterns in salivary duct carcinoma identify prognostic subgroups

Mueller, Simon A., , Blackburn, James, Grady, John P., Kraitsek, Spiridoula, Hajdu, Elektra, Dettmer, Matthias S., Dahlstrom, Jane E., Lee, C. Soon, Luk, Peter P., Yu, Bing, Giger, Roland, Kummerfeld, Sarah, Clark, Jonathan R., Gupta, Ruta, & Cowley, Mark J. (2020) Molecular patterns in salivary duct carcinoma identify prognostic subgroups. Modern Pathology, 33(10), pp. 1896-1909.

Free-to-read version at publisher website

Description

Salivary duct carcinoma (SDCa) is a rare cancer with high rate of metastases and poor survival despite aggressive multimodality treatment. This study analyzes the genetic changes in SDCa, their impact on cancer pathways, and evaluates whether molecular patterns can identify subgroups with distinct clinical characteristics and outcome. Clinicopathologic details and tissue samples from 66 patients (48 males, 18 females) treated between 1995 and 2018 were obtained from multiple institutions. Androgen receptor (AR) was assessed by immunohistochemistry, and the Illumina TruSight 170 gene panel was used for DNA sequencing. Male gender, lympho-vascular invasion, lymph node metastasis, and smoking were significant predictors of disease-free survival. AR was present in 79%. Frequently encountered alterations were mutations in TP53 (51%), PIK3CA (32%) and HRAS (22%), as well as amplifications of CDK4/6 (22%), ERBB2 (21%), MYC (16%), and deletions of CDKN2A (13%). TP53 mutation and MYC amplifications were associated with decreased disease-free survival. Analysis of cancer pathways revealed that the PI3K pathway was most commonly affected. Alterations in the cell cycle pathway were associated with impaired disease-free survival (HR 2.6, P = 0.038). Three subgroups based on AR and ERBB2 status were identified, which featured distinct molecular patterns and outcome. Among AR positive SDCa, HRAS mutations were restricted to AR positive tumors without ERBB2 amplification and HRAS mutations featured high co-occurrence with PIK3CA alterations, which seems specific to SDCa. AR negative SDCa were associated with poor disease-free survival in multivariate analysis (HR 4.5, P = 0.010) and none of these tumors exhibited ERBB2 amplification or HRAS mutations. AR and ERBB2 status in SDCa thus classifies tumors with distinct molecular profiles relevant to future targeted therapy. Furthermore, clinical factors such as smoking and molecular features such as MYC amplification may serve as markers of poor prognosis of SDCa.

Impact and interest:

15 citations in Scopus
Search Google Scholar™

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 248687
Item Type: Contribution to Journal (Journal Article)
Refereed: Yes
ORCID iD:
Gauthier, Marie Emilie A.orcid.org/0000-0002-5256-9165
Measurements or Duration: 14 pages
DOI: 10.1038/s41379-020-0576-2
ISSN: 0893-3952
Pure ID: 169307042
Funding Information: This work was supported by a Cancer Institute NSW Early Career Fellowship (grant number 13/ECF/1–46) to [MJC], Cancer Institute NSW Career Development Fellowship (grant number 2019/ CDF004) to [MJC], NSW Health Early-Mid Career Fellowship, Cancer Council NSW (grant number RG 15–19) to [MJC], and philanthropic donations from the Kinghorn Foundation as well as the Neal Wald Trust.
Copyright Owner: 2020 The Authors
Copyright Statement: This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au
Deposited On: 24 May 2024 00:46
Last Modified: 02 Jul 2024 12:02